N-terminal Modified Recombinant Human Nerve Growth Factor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Recombinant human nerve growth factor (rhNGF) has a short half-life in the body, requiring daily administration and posing challenges in maintaining bioactivity and batch consistency due to multiple modifications during protein modification processes.
Innovation Solution
A polymer of specific N-disubstituted amino acetamino aldehyde derivative is covalently bound to the N-terminal α-amino group of rhNGF under optimized conditions, including a molar ratio, pH range, and reaction time, using sodium cyanoborohydride as a reducing agent, to extend the half-life and preserve bioactivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If protein modification is performed to extend half-life, then the in vivo stability and half-life are improved, but multiple modifications occur leading to loss of batch consistency and bioactivity
Solution Approach 1:
The patent applies local quality by directing the modification reaction specifically to the N-terminal α-amino group of rhNGF through optimized reaction conditions (pH 5.0-6.0, specific polymer-to-protein ratio, temperature control). This localized modification approach ensures that only the intended site on the protein molecule is modified, preventing random multiple modifications at various sites and thereby maintaining batch consistency while extending half-life.
Solution Approach 2:
The patent employs parameter changes by optimizing key reaction parameters including pH (maintained at 5.0-6.0), temperature (4℃-25℃), and the ratio of polymer to protein (1:10 to 10:1). These controlled parameter changes create optimal conditions for selective single modification at the N-terminal group, preventing multiple modifications and ensuring consistent product quality across batches while achieving the desired half-life extension.
2Duration of action of stationary object
If protein modification is performed to extend half-life, then the in vivo stability is improved, but the original bioactivity is lost
Solution Approach 1:
The modification is localized to the N-terminal α-amino group, which is spatially separated from the critical bioactive regions of the rhNGF molecule. This local modification approach allows the polymer to attach without interfering with the conformational structure or binding sites necessary for bioactivity, thus extending half-life while preserving the original biological function.
Solution Approach 2:
The patent uses controlled partial action by limiting the modification to a single polymer attachment per protein molecule through optimized reaction conditions. By controlling the polymer-to-protein ratio and reaction parameters, the modification is kept partial (single site) rather than excessive (multiple sites), which prevents over-modification that would disrupt bioactivity while still achieving sufficient half-life extension.
3Duration of action of stationary object
If multiple modifications occur during protein modification, then more polymer chains are attached, but material is wasted and economic cost increases
Solution Approach 1:
The patent optimizes the polymer-to-protein molar ratio to a specific range (1:10 to 10:1) and controls reaction parameters (pH 5.0-6.0, temperature 4℃-25℃) to achieve high conversion efficiency. These parameter optimizations ensure that the majority of polymer molecules react with protein molecules in a 1:1 stoichiometry, minimizing waste of expensive polymer material while achieving effective half-life extension.
Solution Approach 2:
The patent employs sodium cyanoborohydride as a reducing agent to facilitate the reductive amination reaction between the polymer and protein. This chemical mechanism substitution enables controlled and efficient coupling, ensuring that polymer chains are attached selectively and efficiently to the N-terminal group, reducing material waste from unreacted or improperly attached polymer while achieving the desired pharmacokinetic improvement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified rhNGF exhibits a significantly longer half-life and preserved bioactivity, with over 83% of products being singly modified, reducing economic costs and improving pharmacokinetic profiles.
Implementation Method 1
reacting the rhNGF with the polymer of formula A in the presence of sodium cyanoborohydride serving as a reducing agent
Data Source
AI summary
A modified recombinant human nerve growth factor (modified rhNGF) is obtained from the reaction between a polymer of formula A and an rhNGF. The polymer of formula A is an N-disubstituted amino acetamino aldehyde derivative. Experimental results have shown that the modified rhNGF has a higher in vivo plasma concentration and a longer in vivo half-life than when the rhNGF is not modified or is modified by monomethoxy polyglycol, and that the modified rhNGF preserves the original activity of the unmodified rhNGF. Moreover, the method of preparing the modified rhNGF is low-cost, and the modified products are highly consistent.